Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Breast Neoplasms 19 Neoplasms 11 Polycystic Ovary Syndrome 9 Neoplasm Metastasis 4 Multiple Myeloma 4 Melanoma 4 Vomiting 3 Prostatic Neoplasms 3 Leukemia, Myeloid, Acute 3 Head and Neck Neoplasms 3 Endometrial Neoplasms 3 Triple Negative Breast Neoplasms 2 Solid Tumors 2 Skin Neoplasms 2 Sarcoma 2 Recurrence 2 Precursor Cell Lymphoblastic Leukemia-Lymphoma 2 Peripheral Nervous System Diseases 2 Ovarian Neoplasms 2 Obesity 2 Nausea 2 Lung Neoplasms 2 Leukemia, Lymphocytic, Chronic, B-Cell 2 Leukemia, B-Cell 2 Leukemia 2 Insulin Resistance 2 Inflammation 2 Diabetes Mellitus 2 Colorectal Neoplasms 2 Cognitive Dysfunction 2

Interventions

Nivolumab 143 pembrolizumab 129 Sunitinib 127 Bevacizumab 71 Everolimus 70 Sorafenib 68 cabozantinib 64 Ipilimumab 61 pazopanib 58 Axitinib 57 aldesleukin 51 Magnetic Resonance Spectroscopy 43 Cyclophosphamide 40 Interleukin-2 38 lenvatinib 36 Radiosurgery 36 Specimen Handling 33 Interferon-alpha 32 atezolizumab 29 belzutifan 24 temsirolimus 23 Gemcitabine 23 fludarabine phosphate 22 Radiotherapy 18 Interferon alpha-2 18 Biopsy 18 fludarabine 17 durvalumab 17 avelumab 17 Paclitaxel 16

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × Carcinoma, Renal Cell × Tablets × Clear all

NCT01865747 2021-04-27

METEOR

Exelixis

Phase 3 Completed

658 enrolled 15 charts

Carcinoma, Renal Cell

Data powered by HemOnc (CC BY 4.0) Colophon ⚡